AngioDynamics Earnings Calls

Q1 2025 Beat
$0.0300 (123.08%)
Release date Apr 02, 2025
EPS estimate -$0.130
EPS actual $0.0300
EPS Surprise 123.08%
Revenue estimate 74.256M
Revenue actual 72.004M
Revenue Surprise -3.03%
Q4 2024 Beat
-$0.0400 (63.64%)
Release date Jan 08, 2025
EPS estimate -$0.110
EPS actual -$0.0400
EPS Surprise 63.64%
Revenue estimate 70.567M
Revenue actual 72.845M
Revenue Surprise 3.23%
Q3 2024 Beat
-$0.110 (26.67%)
Release date Oct 03, 2024
EPS estimate -$0.150
EPS actual -$0.110
EPS Surprise 26.67%
Revenue estimate 67.93M
Revenue actual 67.491M
Revenue Surprise -0.646%
Q2 2024 Beat
-$0.0600 (70.00%)
Release date Jul 16, 2024
EPS estimate -$0.200
EPS actual -$0.0600
EPS Surprise 70.00%
Revenue estimate 70.85M
Revenue actual 70.98M
Revenue Surprise 0.183%

Last 4 Quarters for AngioDynamics

Below you can see how ANGO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Jul 16, 2024
Fiscal end date May 31, 2024
Price on release $7.51
EPS estimate -$0.200
EPS actual -$0.0600
EPS surprise 70.00%
Date Price
Jul 10, 2024 $5.60
Jul 11, 2024 $6.13
Jul 12, 2024 $6.00
Jul 15, 2024 $5.93
Jul 16, 2024 $7.51
Jul 17, 2024 $7.40
Jul 18, 2024 $6.95
Jul 19, 2024 $7.18
Jul 22, 2024 $7.13
4 days before 34.11%
4 days after -5.06%
On release day -1.46%
Change in period 27.32%
Q3 2024 Beat
Release date Oct 03, 2024
Fiscal end date Aug 31, 2024
Price on release $6.37
EPS estimate -$0.150
EPS actual -$0.110
EPS surprise 26.67%
Date Price
Sep 27, 2024 $7.66
Sep 30, 2024 $7.78
Oct 01, 2024 $7.63
Oct 02, 2024 $7.65
Oct 03, 2024 $6.37
Oct 04, 2024 $6.10
Oct 07, 2024 $6.10
Oct 08, 2024 $5.88
Oct 09, 2024 $6.08
4 days before -16.84%
4 days after -4.55%
On release day -4.24%
Change in period -20.63%
Q4 2024 Beat
Release date Jan 08, 2025
Fiscal end date Nov 30, 2024
Price on release $12.94
EPS estimate -$0.110
EPS actual -$0.0400
EPS surprise 63.64%
Date Price
Jan 02, 2025 $8.98
Jan 03, 2025 $9.08
Jan 06, 2025 $9.27
Jan 07, 2025 $9.40
Jan 08, 2025 $12.94
Jan 10, 2025 $12.30
Jan 13, 2025 $12.46
Jan 14, 2025 $11.80
Jan 15, 2025 $12.17
4 days before 44.10%
4 days after -5.95%
On release day -4.95%
Change in period 35.52%
Q1 2025 Beat
Release date Apr 02, 2025
Fiscal end date Feb 28, 2025
Price on release $10.86
EPS estimate -$0.130
EPS actual $0.0300
EPS surprise 123.08%
Date Price
Mar 27, 2025 $9.83
Mar 28, 2025 $9.50
Mar 31, 2025 $9.39
Apr 01, 2025 $9.66
Apr 02, 2025 $10.86
Apr 03, 2025 $9.82
Apr 04, 2025 $9.11
Apr 07, 2025 $9.31
Apr 08, 2025 $9.00
4 days before 10.48%
4 days after -17.13%
On release day -9.58%
Change in period -8.44%

AngioDynamics Earnings Call Transcript Summary of Q1 2025

Q1 Financial Performance

Total revenue was $67.5 million, a year-over-year increase of 1.1%.

  • The MedTech segment achieved approximately 9% growth, primarily driven by strong sales of Auryon and AlphaVac.
  • Adjusted EBITDA loss narrowed to $200,000, an improvement from $1.1 million in Q1 FY 2024.
  • Adjusted net loss was $4.4 million, or a loss of $0.11 per share, improved from a loss of $6.2 million ($0.16 per share) year-over-year.

Growth Drivers

  • Auryon: Revenue increased by 25% to $13.7 million. Recent CE mark approval opens access to the European market where a limited release has begun.
  • AlphaVac: Showed strong growth with a 21% increase in revenue, bolstered by positive physician feedback and successful clinical data from the APEX trial.
  • AngioVac: Stabilization reported with $5.8 million in revenue, showing sequential growth.
  • NanoKnife: Revenue declined 6.9% due to tough comparisons, but adoption rates among urologists are encouraging.

Cost Management and Manufacturing Transition

  • Transition to outsourced manufacturing is on track, with expected annual savings of approximately $15 million by FY 2027.
  • Gross margins for the quarter were 54.4%, slightly below last year but ahead of expectations, driven by product mix shifting toward higher-margin MedTech products.

Cash Position

  • Cash and cash equivalents stood at $55 million; however, the company used $18.3 million in operating cash during Q1.
  • Stock repurchase program approved, with approximately $500,000 worth of stock purchased at an average price of $7.62.

Guidance for FY 2025

  • Revenue guidance maintained in the range of $282 million to $288 million, indicating growth of 4.2% to 6.4% over FY 2024.
  • Expected MedTech sales growth of 10% to 12%, and Med Device growth of 1% to 3%.
  • Anticipated gross margin in the range of 52% to 53%, and adjusted EBITDA expected to show a loss of $2.5 million to breakeven.

Future Product Launches & Market Expansion

  • Plans for further penetration into hospital markets for Auryon.
  • AlphaVac to undergo ongoing commercial push and new enhancements scheduled for release.
  • FDA approval expected for NanoKnife by the end of calendar 2024, with a pursuit for reimbursement clarity through CPT code applications.

Market Dynamics

  • Anticipated disruptions in international orders have been noted but are expected to normalize as distributor relationships solidify.
  • Management emphasizes strong feedback on current products and ongoing market demand.

Conclusion

AngioDynamics is showing solid revenue growth, driven by key products in its MedTech segment, while also improving its cash position and narrowing losses. The company is focused on strategic product launches and operational efficiencies that promise to enhance profitability in the coming quarters, making it a company to watch as it capitalizes on growth opportunities in the medical technology space.

AngioDynamics Earnings History

Earnings Calendar

FAQ

When is the earnings report for ANGO?
AngioDynamics (ANGO) has scheduled its earnings report for Jul 15, 2025 before the markets open.

What is the ANGO price-to-earnings (P/E) ratio?
ANGO P/E ratio as of Apr 23, 2025 (TTM) is -9.13.

What is the ANGO EPS forecast?
The forecasted EPS (Earnings Per Share) for AngioDynamics (ANGO) for the first fiscal quarter 2025 is -$0.100.

What are AngioDynamics's retained earnings?
On its balance sheet, AngioDynamics reported retained earnings of $72.00 million for the latest quarter ending Feb 28, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ANGIODYNAMICS
AngioDynamics
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequ...
GOLDEN STAR
Ticker Change Signal Date
I
IBTF
$23.34
0.0857% Apr 21
AN
$165.78
1.88% Apr 17
S
SLQD
$49.97
0.0600% Apr 15
B
BNDW
$68.54
0.146% Apr 15
I
ISTB
$48.11
0.187% Apr 15

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE